Loading...
Projects / Programmes source: ARIS

Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin (Slovene)

Periods
Research activity

Code Science Field Subfield
1.09.00  Natural sciences and mathematics  Pharmacy   
1.04.00  Natural sciences and mathematics  Chemistry   
4.06.00  Biotechnical sciences  Biotechnology   
3.04.00  Medical sciences  Oncology   
Evaluation (rules)
source: COBISS
Researchers (44)
no. Code Name and surname Research area Role Period No. of publicationsNo. of publications
1.  21456  PhD Marko Anderluh  Pharmacy  Researcher  2004 - 2008  372 
2.  27588  PhD Andrej Babič  Pharmacy  Researcher  2007 - 2008  19 
3.  22658  PhD Mateja Cegnar  Pharmacy  Researcher  2007  91 
4.  19062  PhD Jožko Cesar  Pharmacy  Researcher  2004 - 2008  69 
5.  26512  PhD Rok Frlan  Pharmacy  Junior researcher  2006 - 2008  117 
6.  15284  PhD Stanislav Gobec  Pharmacy  Researcher  2004 - 2008  849 
7.  24400  PhD Janez Ilaš  Pharmacy  Researcher  2005 - 2008  257 
8.  26496  PhD Žiga Jakopin  Pharmacy  Junior researcher  2006 - 2008  198 
9.  28220  PhD Damjan Janeš  Pharmacy  Researcher  2008  233 
10.  22728  PhD Sandra Javernik Rajh  Pharmacy  Researcher  2004 - 2008 
11.  22311  PhD Javor Kac  Pharmacy  Researcher  2006  71 
12.  29755  Boštjan Kalamar    Technical associate  2007 - 2008 
13.  21459  PhD Nataša Karas Kuželički  Pharmacy  Researcher  2008  178 
14.  01463  PhD Danijel Kikelj  Pharmacy  Head  2004 - 2008  568 
15.  27782  PhD Andreja Kovač  Pharmacy  Researcher  2007 - 2008  84 
16.  22660  PhD Andreja Kranjc  Pharmacy  Researcher  2004 - 2008  23 
17.  00839  PhD Aleš Krbavčič  Pharmacy  Researcher  2004 - 2008  346 
18.  17436  Marija Krbavčič    Technical associate  2004 - 2008 
19.  18387  PhD Aleš Mlinarič  Pharmacy  Researcher  2004 - 2006  166 
20.  12443  PhD Irena Mlinarič Raščan  Pharmacy  Researcher  2004 - 2008  540 
21.  23419  PhD Janez Mravljak  Pharmacy  Researcher  2004 - 2008  205 
22.  17437  Marjeta Mulej    Technical associate  2004 - 2008 
23.  23418  PhD Jernej Murn  Pharmacy  Junior researcher  2004 - 2006  16 
24.  23421  PhD Kristina Nadrah  Microbiology and immunology  Junior researcher  2004 - 2008  79 
25.  19061  PhD Aleš Obreza  Pharmacy  Researcher  2004 - 2008  334 
26.  28861  PhD Stane Pajk  Pharmacy  Junior researcher  2008  196 
27.  25493  PhD Andrej Perdih  Pharmacy  Junior researcher  2005 - 2006  274 
28.  19317  PhD Lucija Peterlin Mašič  Pharmacy  Researcher  2004 - 2008  411 
29.  20246  PhD Andrej Preželj  Biochemistry and molecular biology  Researcher  2004 - 2005  38 
30.  23549  PhD Robert Roškar  Pharmacy  Researcher  2005 - 2008  309 
31.  08519  PhD Marija Sollner Dolenc  Pharmacy  Researcher  2004 - 2008  661 
32.  25490  PhD Matej Sova  Pharmacy  Junior researcher  2005 - 2008  164 
33.  28862  PhD Roman Šink  Pharmacy  Researcher  2007 - 2008  36 
34.  29903  PhD Veronika Škedelj  Pharmacy  Technical associate  2008  29 
35.  20372  PhD Petra Štefanič  Pharmacy  Researcher  2004 - 2005  33 
36.  21458  PhD Katja Štrancar  Pharmacy  Researcher  2004  31 
37.  28334  PhD Tihomir Tomašić  Pharmacy  Junior researcher  2007 - 2008  390 
38.  29773  PhD Samo Turk  Pharmacy  Researcher  2007 - 2008  88 
39.  09635  PhD Andrej Umek  Pharmacy  Researcher  2004 - 2008  171 
40.  01878  PhD Uroš Urleb  Pharmacy  Researcher  2004 - 2005  381 
41.  17438  Damijana Zalar    Technical associate  2004 - 2008 
42.  18633  PhD Anamarija Zega  Pharmacy  Researcher  2004 - 2008  187 
43.  28905  PhD Nace Zidar  Pharmacy  Junior researcher  2007 - 2008  226 
44.  26493  PhD Matej Živec  Pharmacy  Junior researcher  2006 - 2008  20 
Organisations (1)
no. Code Research organisation City Registration number No. of publicationsNo. of publications
1.  0787  University of Ljubljana, Faculty of Pharmacy  Ljubljana  1626973  17,415 
Abstract
.
Significance for science
Scientific Importance of results of the research programme ''Medicinal chemistry – drug design, synthesis and evaluation'' in the period 2004 - 2008 resides in discovery of novel potential antibacterial and antithrombotic drugs as well as in development of methods for their design, synthesis and study of their molecular mechanism of action. The research programme made an important contribution to discovery of antibacterial drugs which inhibit intracellular steps of bacterial cell wall biosynthesis. Discovery of novel antibacterial drugs is a great challenge to science due to a threatening bacterial resistance to currently used antibacterial drugs. There is also an urgent need for development of new antithrombotic drugs due to a high incidence of thrombotic diseases in the developed countries. The concept of dual antithrombotic drugs which is one of most important results of the research programme could lead to antithrombotic drugs of the future. Novel modulators of integrin receptors, which were developed in the programme, possess a potential as future antitumour and antithrombotic drugs as well. Our contribution to understanding the process of apoptosis regulation opens new possibilities for search of novel proapoptotic molecules and their application in therapy. New molecular tools for electron paramagnetic resonance spectroscopy, which were developed, enable studies of mechanism of action of a number of drugs, of their interactions with biological membranes and their influence on transmembrane signaling. Development of new peptide mimetics, glycomimetics and lipidomimetics, development of new approaches to rational design and synthesis of potential drugs as well as development of novel general synthetic methods and strategies are also important for science.
Significance for the country
Discovery of novel innovative drugs and introducing them to the market in cooperation with strategic partners is a way to assure a sustained growth to Slovenian pharmaceutical industry which is currently one of major players in the Slovenian economy. The current generic nature of the Slovenian pharmaceutical industry does not preclude its evolution into research-oriented industry and education of scientists in a programme like this importantly contributes to this crucial socio-economic tak. Novel drug molecules and lead compounds which emerged from the research programme ''Medicinal chemistry – Drug design, synthesis and evaluation'' in a period from 2004 to 2008 can be a good starting point for development of innovative medicines in cooperation of the Slovenian and international pharmaceutical industry. Young scientists educated in the research programme in period from 2004 to 2008 are perfectly trained and possess competences for scientifically creative work in pharmaceutical industry, where they are expected to create novel research focuses. They are also perfectly trained for research work at university, other research institutes and govermental agencies. In the past period the research programme ''Medicinal chemistry - Drug design, synthesis and evaluation'' generated a substantial amount of new knowledge which is of paramount importance for sustained development of pharmaceutical industry and drug – oriented research in Slovenia. Scientific excellence, which was and remains one of major goals of the research programme, contributed to affirmation of Slovenian science through publications in leading scientific journals. This contributed to creation and preservation of the country's nationmal identity in Europe and in the world.
Most important scientific results Final report, complete report on dLib.si
Most important socioeconomically and culturally relevant results Final report, complete report on dLib.si
Views history
Favourite